Zane Ellen M, a director at Boston Scientific, sold 12,891 shares, indicating potential insights into the company's future prospects.The FARAPULSE system's sales surged by 63% in Q3 2025, with expectations of significant market penetration for Pulsed Field Ablation (PFA) technology.Boston Scientific's financial health is strong, with a P/E ratio of approximately 52.64 and a moderate debt-to-equity ratio of about 0.54.Boston Scientific Corporation (NYSE: BSX) is a leading medical device company known for its ...

Key Takeaways Boston Scientific's EP sales jumped 63% in Q3, fueled by robust FARAPULSE-driven growth.FDA approval expands BSX's FARAPULSE use to treat persistent atrial fibrillation patients.Boston Scientific targets 50% PFA penetration by end-2025, rising to 80% globally by 2028.Boston Scientific’s (BSX) Electrophysiology (“EP”) sales surged 63% in the third quarter of 2025, reflecting continued share gains in the overall EP market. FARAPULSE, the company’s Pulsed Field Ablation (“PFA”) System, drove stro ...